Ivastine (Rivastigmine)

Rivastigmine reversibly inhibits both acetylcholinesterase and butyrylcholinesterase enzymes in the brain. By blocking these enzymes, it prevents the breakdown of acetylcholine, increasing its concentration at synaptic junctions and enhancing cholinergic signaling, which is typically reduced in Alzheimer’s and Parkinson’s disease dementia.

The specific dose of Ivastine is determined by the prescribing healthcare professional based on the patient’s clinical condition, tolerability, and response. The transdermal patch is available in defined strengths, and the prescriber will select the appropriate patch size and schedule, adjusting as needed during treatment.

Safety data for rivastigmine in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss the uncertainties and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Ivastine. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details, and any necessary import documentation.

Ivastine delivers rivastigmine via a transdermal patch, offering steady drug exposure and potentially fewer gastrointestinal side effects compared with oral cholinesterase inhibitors such as donepezil or galantamine. The patch also provides convenience of once‑daily application, but individual response and tolerability vary, so clinicians choose the agent best suited to each patient.

Store Ivastine at room temperature, preferably below 30 °C, in its original packaging. Protect the patches from moisture, direct sunlight, and extreme temperatures. Keep them out of reach of children and do not use patches that appear damaged or expired.

The patch is applied to clean, dry, hair‑free skin on the upper back, upper arm, or chest. Press the patch firmly for several seconds to ensure good contact, then replace it with a new patch according to the prescribed schedule, typically every 24 hours. Rotate application sites to minimize skin irritation.

Serious adverse reactions may include severe skin reactions such as rash or dermatitis, bradycardia, syncope, gastrointestinal bleeding, and rare cases of anaphylaxis. Patients should be monitored for these events, and any signs of severe side effects require immediate medical attention and possible discontinuation of therapy.

Ivastine is contraindicated in individuals with known hypersensitivity to rivastigmine or any component of the patch. It should also be avoided in patients with severe cardiac conduction disorders, uncontrolled asthma, or active gastrointestinal ulcer disease. Clinicians must evaluate each patient’s medical history before initiating therapy.